REVACCINATION WITH DIFFERENT COVID-19 VACCINE; COVID REBOUND/ SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a patient of unspecified age, sex, race and ethnic origin. The patient's height, and weight were not reported. The patient's concurrent conditions included: overweight, elevated blood pressure, and bee venom allergy. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: 180S01 expiry: unknown) dose was not reported, 1 total (first dose) administered on 16-MAR-2021 to Left Arm for covid-19 prophylaxis. Concomitant medications included rosuvastatin. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient received two doses of Non-company suspect vaccine elasomeran (dose number in series 2) (batch number: 93990S expiry: unknown, form of admin, route of admin were not reported) dose was not reported, administered on 01-NOV-2021 (second dose) to Left Arm for covid-19 prophylaxis and third dose (batch number: 001M21A expiry: unknown, form of admin and route of admin were not reported) dose was not reported was administered on 13-APR-2022 to Left Arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with two doses of elasomeran (dose number in series 2). The patient received two doses of Non-company suspect vaccine tozinameran (dose number in series 3) (batch number: GH9694 expiry: unknown, form of admin and route of admin was not reported) dose was not reported, administered on 08-SEP-2022 (fourth dose) to Left Arm for covid-19 prophylaxis and fifth dose (batch number: GJ3268 expiry: unknown, form of admin and route of admin was not reported) dose was not reported, administered on 12-MAY-2023 to Left Arm for covid-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with two doses of tozinameran (dose number in series 3). The patient additionally received Non-company suspect vaccine tozinameran (dose number in series 4) (form of admin and route of admin unknown batch number: HG4677 expiry: unknown) dose was not reported, administered on 20-SEP-2023 (Sixth dose) to Left Arm for covid-19 prophylaxis which was associated with revaccination with different covid-19 vaccine (dose number in series 4). On an unspecified date in 2023, the patient experienced suspected covid-19 infection (dose number in series 4). The patient was treated with Paxlovid (nirmatrelvir/ritonavir) (form of admin, route of admin were not reported, batch number: unknown and expiry: unknown) dose was not reported, administered from 06-OCT-2023 to 11-OCT-2023 for treatment of covid-19 (suspected covid-19 infection). On 16-OCT-2023, the patient experienced covid rebound (dose number in series 4). The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, tozinameran, and tozinameran was not applicable. The patient was recovering from covid rebound/ suspected covid-19 infection, and the outcome of revaccination with different covid-19 vaccine was not reported. This report was non-serious.